bioMérieux - First-Half 2013 Results

03 September, 2013

The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on August 30 to approve the consolidated financial statements for the six months ended June 30, 2013.

The meeting was chaired by Jean-Luc Belingard and attended by the Statutory Auditors, who had performed a limited review of the financial statements.

Sales:

€754 million, with a marked acceleration in the second quarter (+ 4%*)

Operating income before non-recurring items in line with objectives: €125 million, or 16.6% of sales

  • Major investments in innovation:
  • R&D expenditure: €88 million, or 11.7% of sales, up 12.5% at constant exchange rates
  • VIDAS® 3 CE-marked and commercially launched in Europe
  • VITEK® MS FDA-cleared for commercialization in North America

2013 financial objectives confirmed

“In the first half, bioMérieux stepped up its investments in innovation and pursued its international expansion,” said Jean-Luc Belingard, Chairman and Chief Executive Officer. “In particular, we began installing VIDAS® 3 systems in late June and continued to prepare for the commercial deployment of our two new clinical microbiology platforms. We saw double-digit growth in emerging markets. In this context of strong investments, the stability of our interim earnings attests to the financial discipline being applied in every level of our organization. Based on these achievements, we are reaffirming our full-year 2013 targets.”

Download the full report:

Pioneering Diagnostics